Yale Innovation Summit notes thriving CT sector
With global markets continuing to slide, expect valuations to shrink and capital raises to get more difficult for the New Haven area’s bioscience companies, a...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
With global markets continuing to slide, expect valuations to shrink and capital raises to get more difficult for the New Haven area’s bioscience companies, a...
Bioasis, which is developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier, has entered into a research collaboration and license agreement...
Bioasis, which is developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier, has entered into a research collaboration and license agreement...
Connecticut Innovations recently invested $1.25 million in 1906, a recreational cannabis pills company moving its headquarters to the state. “CI’s investment is a major milestone...
Sema4 has completed the acquisition of GeneDx. The transaction establishes Sema4 as one of the largest and most advanced providers of genomic testing in the U.S....
Yale University’s Innovation Summit, which has become Yale’s largest entrepreneurship event and the largest gathering of venture capital investors in Connecticut, returns May 17-18 … more BioLabs, a...
The FDA has approved Camzyos™ from Bristol Myers Squibb (mavacamten for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy...
Pfizer says it will acquire New Haven-based Biohaven Pharmaceuticals, known for its migraine drug Nurtec ODT, for $11.6 billion cash. “Pfizer’s capabilities will accelerate our mission to...
View this email in your browser Career News – May 10, 2022 The Career Expo at the Yale Innovation Summit is open to all Summit attendees who...